1. Home
  2. TRNR vs GRI Comparison

TRNR vs GRI Comparison

Compare TRNR & GRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Interactive Strength Inc.

TRNR

Interactive Strength Inc.

N/A

Current Price

$1.76

Market Cap

2.8M

Sector

Technology

ML Signal

N/A

Logo GRI Bio Inc.

GRI

GRI Bio Inc.

HOLD

Current Price

$1.53

Market Cap

3.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TRNR
GRI
Founded
2017
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Consumer Electronics/Appliances
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.8M
3.0M
IPO Year
2023
2020

Fundamental Metrics

Financial Performance
Metric
TRNR
GRI
Price
$1.76
$1.53
Analyst Decision
Buy
Strong Buy
Analyst Count
2
2
Target Price
$10.00
★ $18.50
AVG Volume (30 Days)
31.7K
★ 46.3K
Earning Date
11-16-2026
11-13-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
N/A
★ N/A
Revenue
★ $11,530,000.00
N/A
Revenue This Year
$117.64
N/A
Revenue Next Year
$10.59
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ 114.31
N/A
52 Week Low
$1.70
$0.18
52 Week High
$3,378.70
$64.12

Technical Indicators

Market Signals
Indicator
TRNR
GRI
Relative Strength Index (RSI) 24.04 37.10
Support Level N/A $1.36
Resistance Level $3.23 $2.33
Average True Range (ATR) 0.12 0.12
MACD 0.23 -0.04
Stochastic Oscillator 14.08 16.18

Price Performance

Historical Comparison
TRNR
GRI

About TRNR Interactive Strength Inc.

Interactive Strength Inc provides an integrated home fitness platform that allows its customers to participate in interactive wellness and strength-based training sessions. Its health coaching services encompass guidance and coaching on nutrition, recovery, sleep, and other health and lifestyle categories. The company generates revenue from sales of its connected fitness products, membership revenue, and personal training revenue.

About GRI GRI Bio Inc.

GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.

Share on Social Networks: